Effective December 20, 2023, Rheumatoid Factor, IgM, Quantitative will be replaced with Rheumatoid Factor.
December 2023
Influenza cases numbers are currently increasing throughout West Michigan. Influenza prevalence guides the most appropriate testing approach and sufficient prevalence has now been reached for influenza rapid antigen or point of care testing (e.g. Sofia instrument) to have improved performance. The use of point of care testing as a screening method during high prevalence reduces both the cost to the patient and turn-around-time as compared to lab-based molecular methods. Point of care tests generally have high analytical specificity, but lack the sensitivity of nucleic acid amplification methods (e.g. PCR). For this reason, PCR testing is still recommended for hospitalized patients and for outpatients with a negative result if influenza is still suspected and if the result will impact clinical decision making.
Low influenza prevalence | High influenza prevalence | |
Recommended order | Influenza PCR | Influenza Point of Care Testing or Influenza PCR |
In pursuit of best practice and alignment, as the only regional laboratory performing Legionella Antigen testing, Corewell Health Ludington will be consolidating this low volume testing by sending it to our core lab.
Beginning January 1, 2024, all specimens for Legionella Antigen, Urine testing collected at Corewell Health Ludington sites will be sent to Corewell Health Reference Laboratory West in Grand Rapids for testing. All other details regarding the test remain the same.
The following information was updated in the Lab Catalog.
Please note that our lab catalog URL has been updated to reflect our new name: CorewellHealth.TestCatalog.org